| Dokumendiregister | Ravimiamet |
| Viit | REP-1/2343-1 |
| Registreeritud | 23.04.2026 |
| Sünkroonitud | 24.04.2026 |
| Liik | Sissetulev kiri |
| Funktsioon | REP Euroopa Farmakopöaga seotud asjaajamine |
| Sari | REP-1 Euroopa Farmakopöa alane kirjavahetus |
| Toimik | REP-1/2026 |
| Juurdepääsupiirang | Avalik |
| Adressaat | European Directorate for the Quality of Medicines & HealthCare |
| Saabumis/saatmisviis | European Directorate for the Quality of Medicines & HealthCare |
| Vastutaja | Signe Leito (RA, Peadirektori asetäitja valdkond, Labor) |
| Originaal | Ava uues aknas |
| Taotle dokumendi eemaldamist või parandamist |
1
Signe Leito
Saatja: [email protected] Saatmisaeg: reede, 17. aprill 2026 17:23 Adressaat: Signe Leito Teema: Proposed addition of a new monograph to the Ph.Eur. work programme:
AMBRISENTAN: EDQM-2026-01985-mail
Järeltegevuse lipp: Järeltegevus Olekulipp: Lipuga märgitud
Please make sure to include in any reply our mail reference: EDQM-2026-01985-mail *************************************************************************** For the attention of NPAs Copy: Presidium Dear colleagues, Please find below the link to a survey being carried out concerning the proposed addition of AMBRISENTAN to the work programme of Group 10D: https://survey.edqm.eu/index.php?r=survey/index&sid=889737&lang=en Deadline for replies: 18 May 2026 With kind regards, On behalf of Mathilde CAPDEROU,
Tiphaine STURTZ Administrative assistant European Pharmacopoeia Department (EPD) EDQM - Council of Europe https://www.edqm.eu [email protected]
****************************************************************************
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
2
Please make sure to include in any reply our mail reference: EDQM-2026-01985-mail